Home » Cell and Gene Therapy

Thought Leadership

Read our insights and commentary about industry news and innovation globally. Subscribe to our monthly newsletter to keep up to date with our thought leadership, news, and updates.

Showing 5 of 10 posts
September 22, 2020 | Blog

CAR-Ts: Barriers and Opportunities for the Migration into Earlier Lines of Therapy in the USA

CAR-Ts offer a significant clinical benefit for patients, however their full potential is currently limited by later line use at sites that are mostly academic centers, combined with significant logistical barriers. In CBPartners’ latest thought leadership article, our healthcare consultants look further into these barriers before assessing the opportunities that could bring CAR-Ts into earlier lines of treatment across oncology.

March 26, 2020 | Podcasts

CBPartners’ Pharma Take-Away: Cell and Gene Therapy Roundtable

In this episode, our host Jared Wolff is joined by healthcare consultants Sophie Katz (a core member of CBPartners' Cell and Gene Therapy Center of Excellence), and Jay Galli to discuss some interesting topics surrounding cell and gene therapies.

gene editing case study
March 24, 2020 | Blog

Genome Editing: An Introduction

A topic that is becoming increasingly popular in the healthcare space is Genome Editing. CBPartners’ Cell and Gene Therapy Center of Excellence team explores the development of these technologies as they present an immense opportunity for the future of the pharmaceutical industry.

blood cells
November 10, 2019 | Blog, News

American Society for Hematology (ASH) 2019 Annual Meeting: CAR T-Cell Therapy Innovation Talks

The American Society of Hematology’s (ASH) annual meeting is a well-established indicator of the innovations that are coming down the pipeline for hematologic diseases. CBPartners’ Cell and Gene Therapy Center of Excellence explored eight promising presentations from the CAR T event.

August 22, 2019 | Blog

CAR T-Cell Therapies: How Close Are We to Meeting the Remaining Needs of Patients?

In 2017, the first therapy designed to genetically modify patients’ own T-cells to attack cancer was FDA-approved, but are CAR T-cell therapies close to meeting the remaining needs of patients? CBPartners' Cell and Gene Therapy Center of Excellence investigates the current challenges and limitations of this therapy.